In this video, Fool health-care bureau chief Brenton Flynn outlines the opportunities for Abbott Labs, most notably with its nutrition, pharmaceutical, and diagnostics divisions. Dietary supplements for older adults -- a growing market in the U.S. -- and pharmaceutical potential, both domestically and in emerging markets, are areas for investors to watch. However, one of Abbott's other divisions faces stiff competition and appears to be fighting significant headwinds. Find out more details in the following video.
Wondering about that new position in your portfolio? For some Abbott Labs shareholders, the new year brought with it a new company called AbbVie. Formerly Abbott's branded-pharmaceuticals business, shares of the new stock were distributed to investors on Jan. 2. To help investors better understand the situation, The Fool has created a brand new premium report on both stocks. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this report by clicking here now.
The article What Are the Opportunities Ahead for Abbott Labs Investors? originally appeared on Fool.com.
Brenton Flynn and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.